{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T22:21:56Z","timestamp":1774045316384,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clgc.2025.102496","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T22:54:23Z","timestamp":1767308063000},"page":"102496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does Physician Documentation of Patients\u2019 Prostate-Specific Antigen Doubling Time Affect Treatment Decisions in High-Risk Biochemically Recurrent Prostate Cancer?"],"prefix":"10.1016","volume":"24","author":[{"given":"Alicia K.","family":"Morgans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maelys","family":"Touya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nader","family":"El-Chaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"ElSouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Mucha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnan","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-2827","authenticated-orcid":false,"given":"Kelechi L.","family":"Adejumo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3173-5918","authenticated-orcid":false,"given":"Tammy","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-9994","authenticated-orcid":false,"given":"Bruce","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parisa","family":"Asgarisabet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prathamesh","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-6419","authenticated-orcid":false,"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clgc.2025.102496_bib0001","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/cancers16040764","article-title":"How the management of biochemical recurrence in prostate cancer will be modified by the concept of anticipation and incrementation of therapy","volume":"16","author":"Sciarra","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.clgc.2025.102496_bib0002","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","article-title":"Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification","volume":"27","author":"Shore","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.clgc.2025.102496_bib0003","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/pros.23967","article-title":"Optimizing the role of androgen deprivation therapy in advanced prostate cancer: challenges beyond the guidelines","volume":"80","author":"Shore","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2025.102496_bib0004","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u24c7) for Prostate Cancer V.2.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Accessed: April 23, 2025."},{"key":"10.1016\/j.clgc.2025.102496_bib0005","unstructured":"\u00a9 European Association of Urology. EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer. Accessed: December 6, 2024. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2024_2024-04-09-132035_ypmy_2024-04-16-122605_lqpk.pdf."},{"issue":"16","key":"10.1016\/j.clgc.2025.102496_bib0006","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2025.102496_bib0007","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41391-024-00894-0","article-title":"Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment","volume":"28","author":"Freedland","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2025.102496_bib0008","unstructured":"Memorial Sloan Kettering Cancer Center. PSA doubling time. Accessed: December 2, 2024. https:\/\/www.mskcc.org\/nomograms\/prostate\/psa_doubling_time."},{"issue":"6","key":"10.1016\/j.clgc.2025.102496_bib0009","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.clgc.2019.08.002","article-title":"PSA doubling time and absolute PSA predict metastasis-free survival in men with biochemically recurrent prostate cancer after radical prostatectomy","volume":"17","author":"Markowski","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"13","key":"10.1016\/j.clgc.2025.102496_bib0010","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1200\/JCO.2006.08.0572","article-title":"Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality","volume":"25","author":"Freedland","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102496_bib0011","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4_suppl","key":"10.1016\/j.clgc.2025.102496_bib0012","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1200\/JCO.2024.42.4_suppl.300","article-title":"What criteria do clinicians use to classify men as \u201chigh risk\u201d among patients with biochemically recurrent nonmetastatic castration-sensitive prostate cancer?","volume":"42","author":"Freedland","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.clgc.2025.102496_bib0013","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1200\/JCO.2024.42.4_suppl.299","article-title":"Real-world treatment patterns for patients with high-risk biochemically recurrent nonmetastatic castration-sensitive prostate cancer","volume":"42","author":"Freedland","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102496_bib0014","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/bco2.158","article-title":"Patterns of care for non-metastatic castration-resistant prostate cancer: a population-based study","volume":"3","author":"Malone","year":"2022","journal-title":"BJUI Compass"},{"issue":"12","key":"10.1016\/j.clgc.2025.102496_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.48707","article-title":"Physician reasons for or against treatment intensification in patients with metastatic prostate cancer","volume":"7","author":"Agarwal","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"17","key":"10.1016\/j.clgc.2025.102496_bib0016","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.clgc.2025.102496_bib0017","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.juro.2008.01.099","article-title":"Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time","volume":"179","author":"Arlen","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102496_bib0018","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/MOU.0000000000001303","article-title":"Prostate-specific antigen doubling time in prostate cancer: a review of calculation methods and clinical implications","volume":"35","author":"Romero Crespo","year":"2025","journal-title":"Curr Opin Urol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102496_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-046588","article-title":"A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design","volume":"11","author":"Freedland","year":"2021","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.clgc.2025.102496_bib0020","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.23.01157","article-title":"PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102496_bib0021","article-title":"Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice","volume":"13","author":"Rosinha","year":"2023","journal-title":"Front Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732500196X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732500196X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:44:17Z","timestamp":1774039457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732500196X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S155876732500196X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102496","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does Physician Documentation of Patients\u2019 Prostate-Specific Antigen Doubling Time Affect Treatment Decisions in High-Risk Biochemically Recurrent Prostate Cancer?","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102496","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102496"}}